Merlin Biotech, Inc.
Biotechnology spinout using clinically validated mRNA platforms to develop therapeutics and vaccines for unmet medical needs, with a lead program encoding USP6 for cancer immunotherapy. The organization pursues preclinical and IND-enabling studies, clinical development planning, and collaborations with translational research centers.
Industries
N/A
Products
Lead mRNA immunotherapy candidate encoding USP6 (lead program)
An mRNA therapeutic candidate encoding the naturally occurring protein USP6 designed to activate multiple immunostimulatory pathways when delivered into tumors; being developed for adult solid tumors and Ewing sarcoma.
Lead mRNA immunotherapy candidate encoding USP6 (lead program)
An mRNA therapeutic candidate encoding the naturally occurring protein USP6 designed to activate multiple immunostimulatory pathways when delivered into tumors; being developed for adult solid tumors and Ewing sarcoma.
Services
Preclinical development and IND-enabling study support
Planning and execution of IND-enabling preclinical studies to support regulatory submissions and early clinical entry.
Clinical study design and development consulting
Protocol and clinical development planning for early-phase trials including Phase I and Phase II planning.
Preclinical development and IND-enabling study support
Planning and execution of IND-enabling preclinical studies to support regulatory submissions and early clinical entry.
Clinical study design and development consulting
Protocol and clinical development planning for early-phase trials including Phase I and Phase II planning.
Expertise Areas
- mRNA therapeutics development
- Cancer immunotherapy
- Vaccine development
- Clinical study design and execution
Key Technologies
- mRNA design and in vitro transcription
- Lipid nanoparticle delivery
- Intratumoral mRNA delivery
- mRNA-encoded protein expression